PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 103336.00004

First Inventor Robert F. Hofmann

Uses of Targeted Oxidative Therapeutic Formulation in Arteriosclerosis

Express Mail Label No. EL619189392US

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents 1. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission 2. 🛛 Applicant claims small entity status. See 37 CFR 1.27. (if applicable, all necessary) a. Computer Readable Form (CRF) [Total Pages з. 🛛 Specification (preferred arrangement set forth below) b. Specification Sequence Listing on: Descriptive title of the Invention □ CD-ROM or CD-R (2 copies); or Cross References to Related Applications ii. 🔲 paper - Statement Regarding Fed sponsored R & D c. Statements verifying identity of above copies Reference to sequence listing, a table, or a computer program listing appendix **ACCOMPANYING APPLICATIONS PARTS** Background of the Invention 9. 🔲 Assignment Papers (cover sheet & document(s)) Brief Summary of the Invention - Brief Description of the Drawings (if filed) 37 C.F.R.§3.73(b) Statement Power of 10. Detailed Description (when there is an assignee) Attorney - Claim(s) - Abstract of the Disclosure 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS 4. Drawing(s) (35 U.S.C.113) [Total Sheets Citations Statement (IDS)/PTO-1449 5. Oath or Declaration [Total Pages 13. 🔲 Preliminary Amendment a. Newly executed (original or copy) 14. 🔯 Return Receipt Postcard (MPEP 503) b. Copy from a prior application (37 CFR 1.63 (d)) (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) Certified Copy of Priority Document(s) 15. 🔲 i. DELETION OF INVENTOR(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) Request and Certification under 35 U.S.C. 122 16. 🔲 named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent. 6. Application Data Sheet. See 37 CFR 1.76 17. 🔲 Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: □ Divisional ☐ Continuation-in-part (CIP) of prior application No _ □ Continuation Group / Art Unit: Prior application information: Examiner For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 17. CORRESPONDENCE ADDRESS or

Correspondence address below ☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) T. Ling Chwang Name Jackson Walker L.L.P. 2435 N. Central Expressway, Suite 600 Address 75080 City TX Zip Code Richardson State 972-744-2919 Fax 972-744-2909 Telephone USA Country Registration No. (Attorney/Agent) 33,590 Name (Print/Type) T. Ling Chwang March 30, 2001 Date Signature

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



NON-PROVISIONAL APPLICATION FOR U. S. PATENT UNDER 37 CFR 1.53(b)

1-66-61

	TRANSMITTAL FORM				
Attorney Docket No. 103336.00004 Assistant Commissioner for Patents Washington, D. C. 20231		"EXPRESS MAILING" Mailing Label No. EL619189392US. Date of Deposit: March 30, 2001. I hereby certify that this paper is being deposited with the U.S. Postal Service, Express Mail Post Office to Addressee Service under 37 CFR 1.10 on the date shown above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.			
	Sir:	Printed Name: M. Outoral			
	Transmitted herewith for filing is the patent application of:	Signature: M. alferal			
	nventor(s): Robert F. Hofmann and Robert H. Carpenter				
	For: USES OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN ARTERIOSCLEROSIS				
Enclosed are: O Sheets of informal drawings and A Declaration/Power of Attorney Assignment with form PTO 1595 X Small Entity Statement					

	FEE CALCULATION				
	NUMBER		NUMBER EXTRA	RATE	BASIC FEE \$ 355.00
Total Claims	55	-20 =	35	X \$9 =	315.00
Independent Claims	4	- 3 =	1	X \$40 =	40.00
		<u> </u>	Tot	al Filing Fee	\$710.00

All correspondence related to this application may be addressed to the undersigned at Jackson Walker, L.L.P., 2435 North Central Expressway, Suite 600, Richardson, Texas 75080.

March 30, 2001	T. W. C.	inac
Date	T. Ling Chwang Reg. No. 33,590	March 30, 2001